Dataset Information

Reinfection with SARS-CoV-2 and Waning Humoral Immunity: A Case Report.

ABSTRACT: Recovery from COVID-19 is associated with production of anti-SARS-CoV-2 antibodies, but it is uncertain whether these confer immunity. We describe viral RNA shedding duration in hospitalized patients and identify patients with recurrent shedding. We sequenced viruses from two distinct episodes of symptomatic COVID-19 separated by 144 days in a single patient, to conclusively describe reinfection with a different strain harboring the spike variant D614G. This case of reinfection was one of the first cases of reinfection reported in 2020. With antibody, B cell and T cell analytics, we show correlates of adaptive immunity at reinfection, including a differential response in neutralizing antibodies to a D614G pseudovirus. Finally, we discuss implications for vaccine programs and begin to define benchmarks for protection against reinfection from SARS-CoV-2.

SUBMITTER: Goldman JD

PROVIDER: S-EPMC9861578 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Reinfection with SARS-CoV-2 and Waning Humoral Immunity: A Case Report.

Goldman Jason D JD Wang Kai K Röltgen Katharina K Nielsen Sandra C A SCA Roach Jared C JC Naccache Samia N SN Yang Fan F Wirz Oliver F OF Yost Kathryn E KE Lee Ji-Yeun JY Chun Kelly K Wrin Terri T Petropoulos Christos J CJ Lee Inyoul I Fallen Shannon S Manner Paula M PM Wallick Julie A JA Algren Heather A HA Murray Kim M KM Hadlock Jennifer J Chen Daniel D Dai Chengzhen L CL Yuan Dan D Su Yapeng Y Jeharajah Joshua J Berrington William R WR Pappas George P GP Nyatsatsang Sonam T ST Greninger Alexander L AL Satpathy Ansuman T AT Pauk John S JS Boyd Scott D SD Heath James R JR

Vaccines 20221220 1

Recovery from COVID-19 is associated with production of anti-SARS-CoV-2 antibodies, but it is uncertain whether these confer immunity. We describe viral RNA shedding duration in hospitalized patients and identify patients with recurrent shedding. We sequenced viruses from two distinct episodes of symptomatic COVID-19 separated by 144 days in a single patient, to conclusively describe reinfection with a different strain harboring the spike variant D614G. This case of reinfection was one of the fi ...[more]

PMID: 36679852

Similar Datasets

Project description:BackgroundInfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) provides natural immunity against reinfection. Recent studies have shown waning of the immunity provided by the BNT162b2 vaccine. The time course of natural and hybrid immunity is unknown.MethodsUsing the Israeli Ministry of Health database, we extracted data for August and September 2021, when the B.1.617.2 (delta) variant was predominant, on all persons who had been previously infected with SARS-CoV-2 or who had received coronavirus 2019 vaccine. We used Poisson regression with adjustment for confounding factors to compare the rates of infection as a function of time since the last immunity-conferring event.ResultsThe number of cases of SARS-CoV-2 infection per 100,000 person-days at risk (adjusted rate) increased with the time that had elapsed since vaccination with BNT162b2 or since previous infection. Among unvaccinated persons who had recovered from infection, this rate increased from 10.5 among those who had been infected 4 to less than 6 months previously to 30.2 among those who had been infected 1 year or more previously. Among persons who had received a single dose of vaccine after previous infection, the adjusted rate was low (3.7) among those who had been vaccinated less than 2 months previously but increased to 11.6 among those who had been vaccinated at least 6 months previously. Among previously uninfected persons who had received two doses of vaccine, the adjusted rate increased from 21.1 among those who had been vaccinated less than 2 months previously to 88.9 among those who had been vaccinated at least 6 months previously.ConclusionsAmong persons who had been previously infected with SARS-CoV-2 (regardless of whether they had received any dose of vaccine or whether they had received one dose before or after infection), protection against reinfection decreased as the time increased since the last immunity-conferring event; however, this protection was higher than that conferred after the same time had elapsed since receipt of a second dose of vaccine among previously uninfected persons. A single dose of vaccine after infection reinforced protection against reinfection.

Dataset Information

Reinfection with SARS-CoV-2 and Waning Humoral Immunity: A Case Report.

Publications

Reinfection with SARS-CoV-2 and Waning Humoral Immunity: A Case Report.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets